IPX203 Achieves High Responder Rates Independent of Fluctuation Severity: Insights From RISE‑PD
Objective: To evaluate responder rates for Good ON time and OFF time with IPX203 using PD diary data from the RISE-PD trial, including comparisons by…Seeing the Full Picture: How Subjective and Objective Data Capture the Daily Impact of Fluctuations in Parkinson’s disease.
Objective: To characterize the frequency, phenomenology, subjective relevance, and daily life impact of motor and non-motor fluctuations in a multicenter cohort of Parkinson’s disease (PD)…Evaluating the Conversion of Immediate-Release and/or Extended-Release Levodopa to IPX203 in Patients with Parkinson’s Disease
Objective: This quality improvement (QI) project was conducted to evaluate the impact of the conversion from immediate-release (IR) and/or extended-release (ER) levodopa (LD) to mucoadhesive polymer…Wearable IMU-Based Gait Analysis Reveals Pharmacological Freezing-of-Gait Phenotypes in Parkinson Disease: A Longitudinal Two-Visit Study
Objective: TolongitudinallyevaluatewearableIMU-derived gaitparameters across two clinical visits andcharacterizepharmacological responsephenotypes inParkinsondiseasepatientswith freezingof gait (FOG). Background: FOG affects upto 80% of patientswith advanced PD and frequentlydemonstrates absent…Ecological Momentary Assessment Monitoring Captures Motor Fluctuation Improvement after DBS in Parkinson’s Disease
Objective: To evaluate whether mobility measures based on ecological momentary assessment (EMAs) capture deep brain stimulation (DBS) motor improvement in Parkinson’s disease (PD) and correlate with clinician-rated motor impairment (UPDRS III) and motor…Sex-Specific Differences in Parkinson’s Disease: A Retrospective Analysis of over 10,000 Patients from the Paracelsus-Elena Hospital, a Specialized Movement Disorder Clinic in Germany
Objective: To analyze sex differences in PD in a large cohort from a hospital specializing in PD and other movement disorders. Background: Sex differences in…Exposure-Response Analysis of Glovadalen in the ATLANTIS Phase II Study: Trial Simulation Explains Dose-Response for OFF Time in Parkinson’s
Objective: This analysis characterized the exposure-response (E-R) relationship of glovadalen (UCB0022) in the ATLANTIS Phase-IIa proof-of-concept study, to understand the apparent lack of dose-response for…Impact of Multi-day Wearable Monitoring on Neurologists’ Assessment of Motor Fluctuations and Treatment Strategies in Parkinson’s Disease: A Real-World Study
Objective: To assess the impact of wearable-device objective metrics on neurologists’ perception and therapeutic decisions in a real-world cohort of patients with Parkinson’s disease (PD).…Markerless Kinematics of Levodopa Response During Activities of Daily Living in Parkinson’s Disease
Objective: To determine whether markerless motion tracking during activities of daily living (ADLs) can identify kinematic changes during medication wearing-off as Parkinson's disease (PD) patients…Motor Fluctuations and Dyskinesias in LRRK2-Associated Parkinson’s Disease
Objective: To characterize motor fluctuations and dyskinesias in patients with LRRK2-associated Parkinson’s disease. Background: Motor complications, including dyskinesias and motor fluctuations, are hallmarks of advanced…
- 1
- 2
- 3
- …
- 29
- Next Page »